One of the leaders in the field of neoantigen based cancer vaccine research is Dr Cathy Wu. She’s a medical oncologist at the Dana-Farber Cancer Institute (DFCI) in Boston, Associate Professor of Medicine at Harvard Medical School and a scientific co-founder of Neon Therapeutics.

Mainz Cathedral

Personalised cancer vaccines are showing exciting promise, and are at the vanguard of what many think of as a renaissance in the field, one that is now attracting the interest of many companies and researchers.

We posted on Neon Therapeutics approach and progress at the JP Morgan Healthcare conference in January, followed by an update on the clinical data from Dr Wu at AACR.

Much has happened since then, however, so it’s a timely juncture to continue the story.

At the recent CRI-CIMT-EATI-AACR international cancer immunotherapy conference in Mainz, Dr Wu kindly spoke to BSB about her research, where it’s at, progress to date, and importantly, where things are heading.

This is the first part in our latest mini-series on the future of cancer vaccines.

Subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by